Bluejay Therapeutics, a San Mateo, CA-based company which specializes in the development of novel therapeutics, raised $182M in Series C funding.
The round was co-led by Frazier Life Sciences with participation from both new and existing investors, including RA Capital Management, T. Rowe Price, Wellington Management, Novo Holdings, RiverVest Venture Partners, Octagon Capital, Arkin Bio Ventures, HBM Healthcare Investments and Unicorn Capital. Following the completion of the Series C financing, Bluejay added Daniel Estes, a General Partner at Frazier, to its Board of Directors.
The company intends to use the funds to accelerate the clinical development of BJT-778, as the treatment for chronic hepatitis D (HDV) and support the progression of additional promising candidates in Bluejay’s robust pipeline for the treatment for chronic hepatitis B.
Led by CEO Dr. Keting Chu, Bluejay Therapeutics is a biopharmaceutical company focused on the development of treatments for viral and liver diseases. Its lead program, BJT-778, is a potentially best-in-class fully human IgG1 monoclonal antibody against hepatitis B surface antigen (anti-HBsAg mAb), being developed for both chronic HBV and HDV. BJT-778 is designed to provide anti-HBV and anti-HDV benefits by neutralizing and clearing HBV and HDV virions as well as by depleting HBsAg-containing subviral particles, which may help to reconstitute a subject’s antiviral immunity and contribute to functional cure for CHB. Bluejay is also developing and advancing other innovative programs for chronic HBV, including a proprietary TLR9 agonist (Cavrotolimod) and a liver targeted transcript inhibitor (BJT-628), with the goal of achieving higher rates of functional cure.
FinSMEs
09/05/2024